PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsFosaprepitant dimeglumine
Fosaprepitant dimeglumine
Emend, Focinvez, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant dimeglumine) is a small molecule pharmaceutical. Fosaprepitant dimeglumine was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Emend, Focinvez, Fosaprepitant dimeglumine (discontinued: Emend, Fosaprepitant dimeglumine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosaprepitant dimeglumine
Tradename
Company
Number
Date
Products
EMENDMerck & CoN-022023 RX2010-11-12
1 products, RLD, RS
FOCINVEZSteriScienceN-216686 RX2023-08-22
1 products, RLD, RS
FOSAPREPITANT DIMEGLUMINETevaN-210064 RX2019-09-05
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
emendNew Drug Application2022-05-04
focinvezNew Drug Application2025-07-22
fosaprepitantANDA2025-07-09
fosaprepitant dimeglumineANDA2024-08-15
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC
2025-05-02D-186
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD12: Aprepitant
HCPCS
No data
Clinical
Clinical Trials
127 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839—R11.1——1——1
NauseaD009325—R11.0——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFosaprepitant dimeglumine
INNaprepitant
Description
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
Classification
Small molecule
Drug classphosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB—
CAS-ID172673-20-0
RxCUI1731071
ChEMBL IDCHEMBL1201782
ChEBI ID64311
PubChem CID219090
DrugBankDB06717
UNII ID6L8OF9XRDC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Emend – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 96 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,323 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use